PAI-1

Summary

Gene Symbol: PAI-1
Description: serpin family E member 1
Alias: PAI, PAI-1, PAI1, PLANH1, plasminogen activator inhibitor 1, endothelial plasminogen activator inhibitor, serine (or cysteine) proteinase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1, serpin E1, serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1
Species: human

Top Publications

  1. doi The plasminogen activator system and cancer
    Brandon McMahon
    Division of Hematology and Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    Pathophysiol Haemost Thromb 36:184-94. 2008
  2. pmc The miR-143/-145 cluster regulates plasminogen activator inhibitor-1 in bladder cancer
    S B Villadsen
    Department of Molecular Biology, Aarhus University, C F Møllers Allé Build, 1130, Aarhus C 8000, Denmark
    Br J Cancer 106:366-74. 2012
  3. ncbi Inactivation of plasminogen activator inhibitor-1 by specific proteolysis with stromelysin-1 (MMP-3)
    H R Lijnen
    Center for Molecular and Vascular Biology and Laboratory for Pharmaceutical Biology and Phytopharmacology, University of Leuven, B 3000 Leuven, Belgium
    J Biol Chem 275:37645-50. 2000
  4. pmc Sphingosine-1-phosphate and interleukin-1 independently regulate plasminogen activator inhibitor-1 and urokinase-type plasminogen activator receptor expression in glioblastoma cells: implications for invasiveness
    Lauren Bryan
    Department of Biochemistry and Molecular Biology, Virginia Commonwealth University School of Medicine, Richmond, VA 23298, USA
    Mol Cancer Res 6:1469-77. 2008
  5. doi Thrombin-activatable fibrinolysis inhibitor genetic polymorphisms as markers of the type of acute coronary syndrome
    Dolors Tassies
    Hemotherapy and Hemostasis Department, Hospital Clinic, Villarroel 170 08036 Barcelona, Spain
    Thromb Res 124:614-8. 2009
  6. ncbi Plasminogen activator inhibitor type 1 gene polymorphism and sepsis
    P W M Hermans
    Department of Pediatrics, Erasmus Medical Center Rotterdam Sophia, Rotterdam, The Netherlands
    Clin Infect Dis 41:S453-8. 2005
  7. pmc Genome-wide association study for circulating levels of PAI-1 provides novel insights into its regulation
    Jie Huang
    National Heart, Lung, and Blood Institute NHBLI Framingham Heart Study, Framingham, MA 01702, USA
    Blood 120:4873-81. 2012
  8. pmc Essential role of plasminogen activator inhibitor type-1 in radiation enteropathy
    Fabien Milliat
    Laboratory of Radiopathology, Institute for Radiological Protection and Nuclear Safety, Fontenay aux Roses Unité Propre de Recherche et de l Enseignement Supérieur, Equipe d Accueil 2710, France
    Am J Pathol 172:691-701. 2008
  9. pmc Comparative proteomic analysis of PAI-1 and TNF-alpha-derived endothelial microparticles
    Danielle B Peterson
    Department of Surgery, Medical College of Wisconsin and Children s Research Institute, Milwaukee, WI 53226, USA
    Proteomics 8:2430-46. 2008
  10. doi Diabetic retinopathy, PAI-1 4G/5G and -844G/A polymorphisms, and changes in circulating PAI-1 levels in Tunisian type 2 diabetes patients
    I Ezzidi
    Faculty of Pharmacy of Monastir, University of Monastir, Monastir, Tunisia
    Diabetes Metab 35:214-9. 2009

Research Grants

  1. Novel Targets in Thrombosis and Atherosclerosis
    Daniel A Lawrence; Fiscal Year: 2012
  2. Workshop on the Molecular and Cellular Biology of Plasminogen Activation
    Victoria Ploplis; Fiscal Year: 2013
  3. Biomarkers of Vascular Disease Progression in Type 1 Diabetes Mellitus
    Maria F Lopes-Virella; Fiscal Year: 2011
  4. William P Fay; Fiscal Year: 2016
  5. RICHARD LOUIS KLEIN; Fiscal Year: 2015
  6. Urokinase, Neutrophil Activation and Acute Lung Injury.
    Gang Liu; Fiscal Year: 2013
  7. DOUGLAS EUGENE VAUGHAN; Fiscal Year: 2016
  8. REGULATION OF VASCULAR FIBRINOLYSIS
    David Loskutoff; Fiscal Year: 2003
  9. MOLECULAR INTERACTIONS OF FIBRINOLYSIS
    John Anagli; Fiscal Year: 2005
  10. Zhongwu Liu; Fiscal Year: 2014

Detail Information

Publications384 found, 100 shown here

  1. doi The plasminogen activator system and cancer
    Brandon McMahon
    Division of Hematology and Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    Pathophysiol Haemost Thromb 36:184-94. 2008
    ..Among the inhibitors of fibrinolysis, PAI-1 is a major player in the pathogenesis of many vascular diseases as well as in cancer...
  2. pmc The miR-143/-145 cluster regulates plasminogen activator inhibitor-1 in bladder cancer
    S B Villadsen
    Department of Molecular Biology, Aarhus University, C F Møllers Allé Build, 1130, Aarhus C 8000, Denmark
    Br J Cancer 106:366-74. 2012
    Upregulation of the proto-oncogene plasminogen activator inhibitor-1 (PAI-1) is a common hallmark of various solid tumours, but the mechanisms controlling its expression are not fully understood.
  3. ncbi Inactivation of plasminogen activator inhibitor-1 by specific proteolysis with stromelysin-1 (MMP-3)
    H R Lijnen
    Center for Molecular and Vascular Biology and Laboratory for Pharmaceutical Biology and Phytopharmacology, University of Leuven, B 3000 Leuven, Belgium
    J Biol Chem 275:37645-50. 2000
    ..Ser(337)-Ser(338) (P10-P9) and Val(341)-Ile(342) (P6-P5) peptide bonds in human plasminogen activator inhibitor-1 (PAI-1). Cleavage is completely abolished in the presence of the metal chelators EDTA or 1,10-phenanthroline...
  4. pmc Sphingosine-1-phosphate and interleukin-1 independently regulate plasminogen activator inhibitor-1 and urokinase-type plasminogen activator receptor expression in glioblastoma cells: implications for invasiveness
    Lauren Bryan
    Department of Biochemistry and Molecular Biology, Virginia Commonwealth University School of Medicine, Richmond, VA 23298, USA
    Mol Cancer Res 6:1469-77. 2008
    ..the plasminogen activator system proteins, including the urokinase-type plasminogen activator (uPA), plasminogen activator inhibitor 1 (PAI-1), and a receptor for uPA (uPAR)...
  5. doi Thrombin-activatable fibrinolysis inhibitor genetic polymorphisms as markers of the type of acute coronary syndrome
    Dolors Tassies
    Hemotherapy and Hemostasis Department, Hospital Clinic, Villarroel 170 08036 Barcelona, Spain
    Thromb Res 124:614-8. 2009
    ..The aim of the study was to investigate the role of genetic polymorphisms in key proteins in fibrinolysis in the type of acute coronary syndrome...
  6. ncbi Plasminogen activator inhibitor type 1 gene polymorphism and sepsis
    P W M Hermans
    Department of Pediatrics, Erasmus Medical Center Rotterdam Sophia, Rotterdam, The Netherlands
    Clin Infect Dis 41:S453-8. 2005
    Plasminogen activator inhibitor type 1 (PAI-1) is a 50-kilodalton glycoprotein of the serine protease inhibitor family. The primary role of PAI-1 in vivo is the inhibition of both tissue- and urokinase-type plasminogen activators...
  7. pmc Genome-wide association study for circulating levels of PAI-1 provides novel insights into its regulation
    Jie Huang
    National Heart, Lung, and Blood Institute NHBLI Framingham Heart Study, Framingham, MA 01702, USA
    Blood 120:4873-81. 2012
    ..study to identify novel associations between genetic variants and circulating plasminogen activator inhibitor-1 (PAI-1) concentration, and examined functional implications of variants and genes that were discovered...
  8. pmc Essential role of plasminogen activator inhibitor type-1 in radiation enteropathy
    Fabien Milliat
    Laboratory of Radiopathology, Institute for Radiological Protection and Nuclear Safety, Fontenay aux Roses Unité Propre de Recherche et de l Enseignement Supérieur, Equipe d Accueil 2710, France
    Am J Pathol 172:691-701. 2008
    ..involved in radiation-induced damage, we hypothesized that its target gene, plasminogen activator inhibitor type 1 (PAI-1), is an essential mediator of intestinal radiation toxicity...
  9. pmc Comparative proteomic analysis of PAI-1 and TNF-alpha-derived endothelial microparticles
    Danielle B Peterson
    Department of Surgery, Medical College of Wisconsin and Children s Research Institute, Milwaukee, WI 53226, USA
    Proteomics 8:2430-46. 2008
    ..generated from human umbilical vein endothelial cells by stimulation with plasminogen activator inhibitor type 1 (PAI-1) or tumor necrosis factor-alpha (TNF-alpha) and subjected to proteomic analysis by LC/MS...
  10. doi Diabetic retinopathy, PAI-1 4G/5G and -844G/A polymorphisms, and changes in circulating PAI-1 levels in Tunisian type 2 diabetes patients
    I Ezzidi
    Faculty of Pharmacy of Monastir, University of Monastir, Monastir, Tunisia
    Diabetes Metab 35:214-9. 2009
    The association of altered plasminogen activator inhibitor (PAI)-1 levels and PAI-1 polymorphisms (4G/5G and -844G/A) with diabetic retinopathy (DR) was investigated in 856 type 2 diabetes (T2D) patients, of whom 383 presented with (DR ..
  11. doi Nox4 mediates the expression of plasminogen activator inhibitor-1 via p38 MAPK pathway in cultured human endothelial cells
    Amandine Jaulmes
    Division of Angiology, Servier Research Institute, 11 rue des Moulineaux, Suresnes, France
    Thromb Res 124:439-46. 2009
    Plasminogen Activator Inhibitor-1 (PAI-1) is the most potent endogenous inhibitor of fibrinolysis which is implicated in the pathogenesis of myocardial infarction and metabolic syndrome...
  12. pmc Plasminogen activator inhibitor type 1 regulates microglial motility and phagocytic activity
    Hyejin Jeon
    Department of Pharmacology, Brain Science and Engineering Institute, CMRI, Kyungpook National University School of Medicine, 101 Dong In, Daegu, Joong Gu, 700 422, South Korea
    J Neuroinflammation 9:149. 2012
    Plasminogen activator inhibitor type 1 (PAI-1) is the primary inhibitor of urokinase type plasminogen activators (uPA) and tissue type plasminogen activators (tPA), which mediate fibrinolysis...
  13. pmc Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects
    Zaid Al-Hamodi
    Department of Molecular Medicine, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia
    Cardiovasc Diabetol 10:23. 2011
    Increased plasma plasminogen activator inhibitor-1 (PAI-1) activity and decreased tissue plasminogen activator (tPA) activity could be considered a true component of the metabolic syndrome (MetS) associated with an increased risk of ..
  14. ncbi Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease
    Claudia Dellas
    Department of Cellular Biology, Division of Vascular Biology, The Scripps Research Institute, La Jolla, California 92037, USA
    Thromb Haemost 93:631-40. 2005
    Although plasminogen activator inhibitor 1 (PAI-1) is one of the primary regulators of the fibrinolytic system, it also has dramatic effects on cell adhesion, detachment and migration...
  15. pmc Co-detection of members of the urokinase plasminogen activator system in tumour tissue and serum correlates with a poor prognosis for soft-tissue sarcoma patients
    H Taubert
    Department of Oral and Maxillofacial Plastic Surgery, Martin Luther University Halle Wittenberg, Halle, Germany
    Br J Cancer 102:731-7. 2010
    ..However, effects of co-expression of members of the uPA system in soft-tissue sarcoma (STS) patients at the protein level in both tumour tissue and serum have not been investigated yet...
  16. pmc Involvement of miR-30c and miR-301a in immediate induction of plasminogen activator inhibitor-1 by placental growth factor in human pulmonary endothelial cells
    Nitin Patel
    Department of Biochemistry and Molecular Biology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    Biochem J 434:473-82. 2011
    b>PAI-1 (plasminogen activator inhibitor-1) is a key physiological inhibitor of fibrinolysis...
  17. pmc Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction
    P Eriksson
    King Gustaf V Research Institute, Department of Medicine, Karolinska Institute, Karolinska Hospital, Stockholm, Sweden
    Proc Natl Acad Sci U S A 92:1851-5. 1995
    Increased plasminogen-activator inhibitor 1 (PAI-1) activity is a common finding in patients with coronary heart disease. Here we provide evidence for an independent, etiological role of PAI-1 in myocardial infarction...
  18. ncbi Plasminogen activator inhibitor 1: physiological and pathophysiological roles
    Bernd R Binder
    Department of Vascular Biology and Thrombosis Research, University of Vienna, A 1090 Vienna, Austria
    News Physiol Sci 17:56-61. 2002
    b>Plasminogen activator inhibitor 1 (PAI-1) inhibits plasminogen activators (u-PA and t-PA) by forming stable complexes endocytosed via a low-density lipoprotein receptor superfamily member-dependent mechanism...
  19. ncbi Promoter (4G/5G) plasminogen activator inhibitor-1 genotype and plasminogen activator inhibitor-1 levels in blacks, Hispanics, and non-Hispanic whites: the Insulin Resistance Atherosclerosis Study
    Andreas Festa
    Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX 78228 3900, USA
    Circulation 107:2422-7. 2003
    The 4G/5G polymorphism of the plasminogen activator inhibitor-1 (PAI-1) gene has been related to cardiovascular disease.
  20. doi A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules
    Hongbin Liu
    Australian Centre for Blood Diseases, Monash University, Prahran, Melbourne, Victoria
    J Endocrinol 201:59-66. 2009
    ..diabetic patients and inhibits tumour necrosis factor alpha (TNF)-mediated plasminogen activator inhibitor type-1 (PAI-1) induction in human vascular endothelial cells...
  21. doi Tumour budding, uPA and PAI-1 are associated with aggressive behaviour in colon cancer
    B Märkl
    Institute of Pathology, Klinikum Augsburg, Augsburg, Germany
    J Surg Oncol 102:235-41. 2010
    The proteases PAI-1 and uPA play a major role in extracellular matrix degradation, which facilitates tumour progression. Tumour budding is a histomorphological expression of enhanced tumour cell migration.
  22. ncbi Relationship between gene polymorphism of the PAI-1 promoter and myocardial infarction
    L Fu
    Cardiovascular Disease Department, Harbin First Affiliated Hospital of Harbin Medical University, Harbin 150001, China
    Chin Med J (Engl) 114:266-9. 2001
    To investigate the association between gene polymorphism of the plasminogen activator inhibitor-1 (PAI-1) and myocardial infarction (MI) in Chinese.
  23. ncbi Evidence for a pre-latent form of the serpin plasminogen activator inhibitor-1 with a detached beta-strand 1C
    Daniel M Dupont
    Laboratory of Cellular Protein Science, Department of Molecular Biology, University of Aarhus, Gustav Wieds Vej 10C, DK 8000 Arhus C, Denmark
    J Biol Chem 281:36071-81. 2006
    Latency transition of plasminogen activator inhibitor-1 (PAI-1) occurs spontaneously in the absence of proteases and results in stabilization of the molecule through insertion of its reactive center loop (RCL) as a strand in beta-sheet A ..
  24. ncbi The effect of the plasminogen activator inhibitor-1 4G/5G polymorphism on the thrombotic risk
    Argirios E Tsantes
    Laboratory of Hematology and Blood Bank Unit, Attikon General Hospital, School of Medicine, University of Athens, Greece
    Thromb Res 122:736-42. 2008
    Plasminogen activator inhibitor (PAI-1), is the central component of the fibrinolytic system. A deletion/insertion (4G/5G) polymorphism in the promoter region of the PAI-1 gene has been correlated with levels of plasma PAI-1...
  25. pmc Cloning and sequence of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor
    T Ny
    Proc Natl Acad Sci U S A 83:6776-80. 1986
    ..immunologically using an antibody probe developed against the beta-migrating plasminogen activator inhibitor (beta-PAI) purified from cultured bovine aortic endothelial cells...
  26. ncbi The organization of the human-plasminogen-activator-inhibitor-1 gene. Implications on the evolution of the serine-protease inhibitor family
    L Strandberg
    Department of Applied Cell and Molecular Biology, Umea University, Sweden
    Eur J Biochem 176:609-16. 1988
    b>Plasminogen activator inhibitor 1 (PAI-1) is a member of the serine protease inhibitor super family (SERPINS) which is thought to play an integral role in the control of plasminogen activation...
  27. ncbi The structural basis for the pathophysiological relevance of PAI-I in cardiovascular diseases and the development of potential PAI-I inhibitors
    Ann Gils
    Laboratory for Pharmaceutical Biology and Phytopharmacology, Katholieke Universiteit Leuven, E Van Evenstraat 4, B 3000 Leuven, Belgium
    Thromb Haemost 91:425-37. 2004
    Plasminogen activator inhibitor-I (PAI-I) is an important component of the plasminogen/plasmin system as it is the main inhibitor of tissue-type and urokinase-type plasminogen activator...
  28. ncbi The plasminogen activator inhibitor-1 (PAI-1) promoter haplotype is related to PAI-1 plasma concentrations in lean individuals
    Maartje Verschuur
    Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands
    Atherosclerosis 181:275-84. 2005
    Elevated plasminogen activator inhibitor-1 (PAI-1) concentrations are associated with cardiovascular diseases. PAI-1 antigen levels are influenced by environmental factors such as body mass index (BMI), and by genetic factors...
  29. doi Plasminogen activator inhibitor 1 is an intracellular inhibitor of furin proprotein convertase
    Denis Bernot
    INSERM, U626, Université de Méditerranée, Faculte de Medecine, 27 Boulevard Jean Moulin, 13385 Marseilles Cedex 5, France
    J Cell Sci 124:1224-30. 2011
    ..Here, we demonstrate that the serine protease inhibitor plasminogen activator inhibitor 1 (PAI-1) forms an SDS-stable complex with the PC furin, which leads to the inhibition of the intra-..
  30. ncbi PAI-1 4G/5G polymorphism and plasma levels association in patients with coronary artery disease
    Luciana Moreira Lima
    Departamento de Medicina e Enfermagem, Universidade Federal de Vicosa, Vicosa, MG, Brazil
    Arq Bras Cardiol 97:462-389. 2011
    Type-1 plasminogen activator inhibitor (PAI-1) 4G/5G polymorphism may influence the PAI-1 expression. High plasma levels of PAI-1 are associated with coronary artery disease (CAD).
  31. ncbi Plasminogen activator inhibitor-1 and vitronectin promote the cellular clearance of thrombin by low density lipoprotein receptor-related proteins 1 and 2
    S Stefansson
    Biochemistry Department, J H Holland Laboratory, American Red Cross, Rockville, Maryland 20855, USA
    J Biol Chem 271:8215-20. 1996
    ..cofactor II (HCII), alpha2-macroglobulin (alpha2-M), protease nexin I, and plasminogen activator inhibitor-1 (PAI-1)...
  32. ncbi Role of the 4G/5G polymorphism of PaI-1 gene promoter on PaI-1 levels in obese patients: influence of fat distribution and insulin-resistance
    M T Sartori
    Department of Medical and Surgical Sciences, University of Padua, Italy
    Thromb Haemost 86:1161-9. 2001
    As PAI-1, a cardiovascular risk factor linked to insulin-resistance, may be influenced by a 4G/5G gene polymorphism in disease states, we studied both PAI-1 plasma concentration (PAI-1:Ag) and 4G/5G polymorphism, and their relationship ..
  33. ncbi The plasminogen activator inhibitor-1 -675 4G/5G genotype influences the risk of myocardial infarction associated with elevated plasma proinsulin and insulin concentrations in men from Europe: the HIFMECH study
    I Juhan-Vague
    Laboratoire d Hematologie, CHU Timone, Inserm EPI 99 36, Marseilles, France
    J Thromb Haemost 1:2322-9. 2003
    Although the potential role of plasminogen activator inhibitor-1 (PAI-1) in the development of coronary artery disease is strongly supported by its biological characteristics, results of clinical studies remain controversial.
  34. ncbi PAI-1 Gene 4G/5G polymorphism and risk of type 2 diabetes in a population-based sample
    James B Meigs
    General Medicine Division, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Obesity (Silver Spring) 14:753-8. 2006
    Elevated plasma levels of plasminogen activator inhibitor-1 (PAI-1) increase risk for type 2 diabetes...
  35. ncbi Association of plasminogen activator inhibitor (PAI)-1 (SERPINE1) SNPs with myocardial infarction, plasma PAI-1, and metabolic parameters: the HIFMECH study
    P E Morange
    INSERM, U626, Universite de la Mediterranee, Marseille, France
    Arterioscler Thromb Vasc Biol 27:2250-7. 2007
    The purpose of this study was to investigate the effects of plasminogen activator inhibitor-1 (PAI-1) gene (SERPINE1) single nucleotide polymorphisms (SNPs) on the risk of myocardial infarction (MI), on PAI-1 levels, and factors related ..
  36. ncbi Cross talk of tumor necrosis factor-alpha and the renin-angiotensin system in tumor necrosis factor-alpha-induced plasminogen activator inhibitor-1 production from hepatocytes
    Yumie Takeshita
    Department of Disease Control and Homeostasis, Kanazawa University Graduate School of Medical Science, Ishikawa, Japan
    Eur J Pharmacol 579:426-32. 2008
    ..the gene expression of renin-angiotensin system components, together with that of plasminogen activator inhibitor (PAI)-1, is upregulated in the liver of patients with obesity and type 2 diabetes...
  37. doi Unique secretory dynamics of tissue plasminogen activator and its modulation by plasminogen activator inhibitor-1 in vascular endothelial cells
    Yuko Suzuki
    Department of Physiology, Hamamatsu University School of Medicine, Hamamatsu, Japan
    Blood 113:470-8. 2009
    ..The addition of PAI-1 dose-dependently facilitated the dissociation of membrane-retained tPA and increased the amounts of tPA-PAI-1 ..
  38. doi Plasminogen activator inhibitor-1 promotes inflammatory process induced by cigarette smoke extraction or lipopolysaccharides in alveolar epithelial cells
    Xia Xu
    Department of Respiratory Diseases, Qilu Hospital, Shandong University, Jinan, Shandong, PR China
    Exp Lung Res 35:795-805. 2009
    Plasminogen activator inhibitor-1 (PAI-1) plays a role in regulating levels of some cytokines and cell migration in addition to its classic role in inhibiting fibrinolysis...
  39. pmc PAI-1 mediates the TGF-beta1+EGF-induced "scatter" response in transformed human keratinocytes
    Jennifer Freytag
    Center for Cell Biology and Cancer Research, Albany Medical College, Albany, New York 12208, USA
    J Invest Dermatol 130:2179-90. 2010
    ..The most highly expressed transcript, identified by mRNA profiling, encoded plasminogen activator inhibitor-1 (PAI-1; SERPINE1)...
  40. doi Genetic variation in hyaluronan metabolism loci is associated with plasma plasminogen activator inhibitor-1 concentration
    Matthew B Lanktree
    Department of Medicine, Robarts Research Institute and Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON, Canada
    Blood 116:2160-3. 2010
    Elevated plasma plasminogen activator inhibitor-1 (PAI-1) concentration is associated with cardiovascular disease risk...
  41. doi Involvement of RAGE, NADPH oxidase, and Ras/Raf-1 pathway in glycated LDL-induced expression of heat shock factor-1 and plasminogen activator inhibitor-1 in vascular endothelial cells
    Ganesh V Sangle
    Department of Physiology, University of Manitoba, Winnipeg, Manitoba, Canada R3E 3P4
    Endocrinology 151:4455-66. 2010
    ..Plasminogen activator inhibitor-1 (PAI-1) is the major physiological inhibitor for fibrinolysis, and it is also implicated in inflammation and tissue ..
  42. doi Role of tissue plasminogen activator and plasminogen activator inhibitor polymorphism in myocardial infarction
    Waqas Ahmed
    Department of Biosciences, COMSATS Institute of Information Technology, Park Road, Islamabad, 45600, Pakistan
    Mol Biol Rep 38:2541-8. 2011
    ..of tissue-plasminogen activator (t-PA) (Alu-repeat insertion (I)/deletion (D)) and plasminogen activator inhibitor (PAI-1) (4G/5G insertion/deletion) polymorphisms with MI in the Pakistani population...
  43. pmc Metabolic factors, adipose tissue, and plasminogen activator inhibitor-1 levels in type 2 diabetes: findings from the look AHEAD study
    L Maria Belalcazar
    Department of Medicine, University of Texas Medical Branch, Galveston, TX 77555 1060, USA
    Arterioscler Thromb Vasc Biol 31:1689-95. 2011
    Plasminogen activator inhibitor-1 (PAI-1) production by adipose tissue is increased in obesity, and its circulating levels are high in type 2 diabetes...
  44. doi Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer
    C Alberti
    Unit of Molecular Therapies, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    Oncogene 31:4139-49. 2012
    ..EGFR activated NFkB-dependent transcription and induced secretion of IL-6 and plasminogen activator inhibitor (PAI-1)...
  45. ncbi Polymorphism 4G/5G in the plasminogen activator inhibitor-1 (PAI-1) gene is associated with IgE-mediated allergic diseases and asthma in the Czech population
    D Buckova
    Department of Pathological Physiology, Medical Faculty, Masaryk University Brno, Kom Namesti 2, 662 43 Brno, Czech Republic
    Allergy 57:446-8. 2002
    Plasminogen activator inhibitor type 1 (PAI-1) is a glycoprotein that belongs to the serine protease inhibitor superfamily and has an essential role in tissue remodeling after inflammation...
  46. ncbi The -675 4G/5G plasminogen activator inhibitor-1 promoter polymorphism in house dust mite-sensitive allergic asthma patients
    A Pampuch
    Department of Allergology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland
    Allergy 61:234-8. 2006
    Plasminogen activator inhibitor (PAI)-1 plays an important role in inflammation and tissue remodeling. Recently, the -675 4G/5G PAI-1 polymorphism has been linked with asthma.
  47. ncbi The influence of metabolic syndrome components on plasma PAI-1 concentrations is modified by the PAI-1 4G/5G genotype and ethnicity
    Nitien Hira Naran
    Department of Chemical Pathology, National Health Laboratory Service and the University of the Witwatersrand, Johannesburg, South Africa
    Atherosclerosis 196:155-63. 2008
    ..disease (CAD) is less common in African than Indian or White subjects and elevated plasminogen activator inhibitor (PAI)-1 levels may be a risk factor for CAD...
  48. ncbi Association of angiotensin converting enzyme and plasminogen activator inhibitor-1 promoter gene polymorphisms with features of the insulin resistance syndrome in patients with premature coronary heart disease
    L Viitanen
    Department of Medicine, University of Kuopio, PO Box 1627, 70 211 Kuopio, Finland
    Atherosclerosis 157:57-64. 2001
    ..enzyme (ACE) (insertion/deletion (I/D) in intron 16) and of the plasminogen activator inhibitor-1 (PAI-1) (promoter 4G/5G) genes have been linked with coronary heart disease (CHD) and/or myocardial infarction (MI)...
  49. ncbi PAI-1 polymorphisms modulate phenotypes associated with the metabolic syndrome in obese and diabetic Caucasian population
    C Lopes
    Hammersmith Genome Centre, Imperial College, London, UK
    Diabetologia 46:1284-90. 2003
    Plasminogen activator inhibitor-1 (PAI-1) is a main regulator of the endogenous fibrinolytic system and modulates the thrombosis progression...
  50. ncbi The -844 G/A PAI-1 polymorphism is associated with mRNA expression in rheumatoid arthritis
    Nora Magdalena Torres-Carrillo
    Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, Departamento de Biología Molecular y Genómica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Col Independencia, Guadalajara, Jalisco 44340, Mexico
    Rheumatol Int 28:355-60. 2008
    We assessed whether the -844 G/A polymorphism and mRNA expression of plasminogen activator inhibitor 1 (PAI-1) gene are associated with rheumatoid arthritis (RA)...
  51. ncbi Differences in plasminogen activator inhibitor 1 in subcutaneous versus omental adipose tissue in non-obese and obese subjects
    G He
    Department of Endocrinology and Metabolism C, Aarhus Kommehospital, Aarhus University Hospital, Aarhus C, Denmark
    Horm Metab Res 35:178-82. 2003
    Human adipose tissue can produce plasminogen activator inhibitor-1 (PAI-1)...
  52. pmc Involvement of hypoxia-inducing factor-1alpha-dependent plasminogen activator inhibitor-1 up-regulation in Cyr61/CCN1-induced gastric cancer cell invasion
    Ming Tsan Lin
    Department of Primary Care Medicine, National Taiwan University Hospital, Taipei, Taiwan
    J Biol Chem 283:15807-15. 2008
    ..HIF-1alpha-regulated invasiveness genes were examined, and we found that only plasminogen activator inhibitor-1 (PAI-1) showed a significant increase in mRNA and protein levels in cells overexpressing Cyr61...
  53. doi Regulation of plasminogen activator inhibitor 1 expression in human osteoarthritic chondrocytes by fluid shear stress: role of protein kinase Calpha
    Chih Chang Yeh
    ChiaYi Veterans Hospital, and Department of Biochemical Science and Technology, National Chiayi University, Chiayi, Taiwan
    Arthritis Rheum 60:2350-61. 2009
    To test a fluid flow system for the investigation of the influence of shear stress on expression of plasminogen activator inhibitor 1 (PAI-1) in human osteoarthritic (OA) articular chondrocytes (from lesional and nonlesional sites) and ..
  54. ncbi Polymorphisms in the ACE and PAI-1 genes are associated with recurrent spontaneous miscarriages
    T Buchholz
    Department of Obstetrics and Gynecology, Grosshadern Hospital, Ludwig Maximilians University, 81377 Munich, Germany
    Hum Reprod 18:2473-7. 2003
    ..Fibrinolysis is tightly regulated by plasminogen activator inhibitor-1 (PAI-1)...
  55. ncbi IL-1 and IL-6 induce hepatocyte plasminogen activator inhibitor-1 expression through independent signaling pathways converging on C/EBPdelta
    Jie Dong
    Cardiovascular Research Institute, Colchester Research Facility, University of Vermont, 208 South Park Drive, Colchester, VT 05446, USA
    Am J Physiol Cell Physiol 292:C209-15. 2007
    ..pathways activated by IL-1 and IL-6 that contribute to increased expression of plasminogen activator inhibitor-1 (PAI-1), we studied human hepatoma (HepG2) cells and primary mouse hepatocytes...
  56. ncbi Alpha 1-antitrypsin mutations in NAFLD: high prevalence and association with altered iron metabolism but not with liver damage
    Luca Valenti
    Department of Internal Medicine, Ospedale Policlinico, Mangiagalli e Regina Elena Fondazione IRCCS, Universita di Milano, Italy
    Hepatology 44:857-64. 2006
    ..047), AAT mutations favoring sinusoidal iron deposition did not affect liver damage. In conclusion, AAT mutations are associated with hyperferritinemia and sinusoidal iron accumulation, but not with more severe liver damage in NAFLD...
  57. ncbi Plasminogen activator inhibitor type 1 is protective during severe Gram-negative pneumonia
    Rosemarijn Renckens
    Center for Infection and Immunity Amsterdam, Department of Pathology, University of Amsterdam, The Netherlands
    Blood 109:1593-601. 2007
    Plasminogen activator inhibitor type-1 (PAI-1) levels are consistently elevated in patients with severe pneumonia and sepsis and highly predictive for an unfavorable outcome...
  58. pmc Plasminogen activator inhibitor-1 and vitronectin expression level and stoichiometry regulate vascular smooth muscle cell migration through physiological collagen matrices
    N Garg
    Department of Internal Medicine, University of Missouri School of Medicine and Research Service, Harry S Truman Memorial Veterans Affairs Hospital, Columbia, MO, USA
    J Thromb Haemost 8:1847-54. 2010
    Vascular smooth muscle cell (VSMC) migration is a critical process in arterial remodeling. Purified plasminogen activator inhibitor-1 (PAI-1) is reported to both promote and inhibit VSMC migration on two-dimensional (D) surfaces.
  59. pmc 4G/5G polymorphism of plasminogen activator inhibitor-1 gene is associated with mortality in intensive care unit patients with severe pneumonia
    Anil Sapru
    Department of Pediatrics, Division of Critical Care Medicine, University of California San Francisco, San Francisco, CA 94143, USA
    Anesthesiology 110:1086-91. 2009
    Higher plasma and pulmonary edema fluid levels of plasminogen activator inhibitor-1 (PAI-1) are associated with increased mortality in patients with pneumonia and acute lung injury...
  60. ncbi Relationship between postrenal transplant osteonecrosis of the femoral head and gene polymorphisms related to the coagulation and fibrinolytic systems in Japanese subjects
    Takeshi Asano
    Department of Orthopaedics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
    Transplantation 77:220-5. 2004
    ..the relationship between the incidence of ONFH and polymorphisms in the genes for plasminogen activator inhibitor (PAI)-1, which is one of the major regulatory proteins of the fibrinolytic system, and 5,10-methylenetetrahydrofolate ..
  61. ncbi Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation
    W P Fay
    Cardiology Division, Ann Arbor Veterans Affairs Hospital, Mich
    N Engl J Med 327:1729-33. 1992
  62. ncbi Plasminogen activator inhibitor type-1: reactive center and amino-terminal heterogeneity determined by protein and cDNA sequencing
    P A Andreasen
    FEBS Lett 209:213-8. 1986
    ..the urokinase-type and tissue-type plasminogen activator can convert their approximately 54 kDa type-1 inhibitor (PAI-1) to an inactive form with a lower apparent molecular mass...
  63. pmc cDNA cloning of human plasminogen activator-inhibitor from endothelial cells
    D Ginsburg
    J Clin Invest 78:1673-80. 1986
    Full-length cDNA for plasminogen activator inhibitor (PAI-1) was isolated from a human umbilical vein endothelial cell (HUVEC) lambda gt11 cDNA library...
  64. ncbi Interfering with the inhibitory mechanism of serpins: crystal structure of a complex formed between cleaved plasminogen activator inhibitor type 1 and a reactive-centre loop peptide
    Y Xue
    Department of Inorganic Chemistry, Goteborg University, Sweden
    Structure 6:627-36. 1998
    Plasminogen activator inhibitor type 1 (PAI-1) is an important endogenous regulator of the fibrinolytic system. Reduction of PAI-1 activity has been shown to enhance dissolution of blood clots...
  65. ncbi Acute phase protein alpha 1-acid glycoprotein interacts with plasminogen activator inhibitor type 1 and stabilizes its inhibitory activity
    J Boncela
    Center for Microbiology and Virology, Polish Academy of Sciences 93 232 Lodz, Poland
    J Biol Chem 276:35305-11. 2001
    ..one of the major acute phase proteins, was found to interact with plasminogen activator inhibitor type 1 (PAI-1) and to stabilize its inhibitory activity toward plasminogen activators...
  66. ncbi The impact of the PAI-1 A((-844))G promoter polymorphism on the risk and extent of coronary heart disease
    Andrea Haselbauer
    Thromb Haemost 88:697-8. 2002
  67. ncbi Evaluation of low PAI-1 activity as a risk factor for hemorrhagic diathesis
    A Agren
    Department of Hematology, Coagulation Unit, King Gustaf V Research Institute, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden
    J Thromb Haemost 4:201-8. 2006
    Prospective studies of the epidemiology and clinical significance of low plasminogen activator inhibitor type 1 (PAI-1) activity are lacking.
  68. doi The plasminogen activator inhibitor-1 (PAI-1) gene -844 A/G and -675 4G/5G promoter polymorphism significantly influences plasma PAI-1 levels in women with polycystic ovary syndrome
    Sun Lin
    Department of Reproductive Endocrinology, The First Affiliated Hospital of Harbin Medical University, No 23 Youzheng Street, Harbin, 150001 Heilongjiang, China
    Endocrine 36:503-9. 2009
    Mutations in the plasminogen activator inhibitor-1 (PAI-1) gene, along with increased PAI-1 levels, have been implicated in the pathogenesis of polycystic ovarian syndrome (PCOS)...
  69. pmc Effects of altered plasminogen activator inhibitor-1 expression on cardiovascular disease
    Victoria A Ploplis
    W M Keck Center for Transgene Research and Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, Indiana, USA
    Curr Drug Targets 12:1782-9. 2011
    Plasminogen Activator Inhibitor-1 (PAI-1) is a multifunctional protein with the ability to not only regulate fibrinolysis through inhibition of plasminogen activation, but also cell signaling events which have direct downstream effects ..
  70. doi Functionally stable plasminogen activator inhibitor-1 in a family with cardiovascular disease and vitiligo
    Mehmet Agirbasli
    Department of Cardiology, Faculty of Medicine, Marmara University Hospital, Yeşilbahar Sok 68 14 Palmiye Apt, Göztepe Kadıköy, 34726, Istanbul, Turkey
    J Thromb Thrombolysis 38:50-6. 2014
    ..In this study, we investigated PAI-1 antigen (Ag) and activity levels in a 34 year old male with extensive vascular disease, alopecia areata and ..
  71. doi The prevalence of 4G/5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in central serous chorioretinopathy and its association with plasma PAI-1 levels
    Esin Sögütlü Sari
    Ophthalmology Department, Faculty of Medicine, Balikesir University, Balikesir, Turkey
    Cutan Ocul Toxicol 33:270-4. 2014
    ..understood disease and the choroidal circulation abnormality induced by the plasminogen activator inhibitor type 1 (PAI-1) seems to be associated with the pathogenesis...
  72. ncbi Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene
    W P Fay
    Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, USA
    Blood 90:204-8. 1997
    Plasminogen activator inhibitor-1 (PAI-1), the primary inhibitor of tissue- and urokinase-type plasminogen activators, is considered a critical regulator of the fibrinolytic system...
  73. ncbi The 4G/4G genotype of the 4G/5G polymorphism of the type-1 plasminogen activator inhibitor (PAI-1) gene is a determinant of penetrating behaviour in patients with Crohn's disease
    M Sans
    Department of Gastroenterology, Institut de Malalties Digestives, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain
    Aliment Pharmacol Ther 17:1039-47. 2003
    ..Crohn's disease is a heterogeneous disorder with polygenic inheritance...
  74. ncbi Association between plasminogen activator inhibitor 1 gene polymorphisms and preeclampsia
    Dora Fabbro
    Department of Biomedical Science and Technology, University of Udine, Udine General Hospital, Piazzale Kolbe 1, IT 33100 Udine, Italy
    Gynecol Obstet Invest 56:17-22. 2003
    It is known that the plasminogen activator inhibitor 1 (PAI-1) protein levels are increased in placentas of preeclamptic subjects...
  75. ncbi Preeclampsia and its interaction with common variants in thrombophilia genes
    M P M De Maat
    Department of Hematology, Erasmus Medical Center, Rotterdam, The Netherlands
    J Thromb Haemost 2:1588-93. 2004
    ..Polymorphisms in the thrombophilia genes [plasminogen activator inhibitor type 1 [PAI-1 -675(4G/5G)], thrombin activatable fibrinolysis inhibitor (TAFI -438G/A and 1040C/T), methylenetetrahydrofolate ..
  76. ncbi Plasminogen activator inhibitor-1: a common denominator in obesity, diabetes and cardiovascular disease
    Bart De Taeye
    Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA
    Curr Opin Pharmacol 5:149-54. 2005
    ..with increased production of the primary inhibitor of endogenous thrombolysis, plasminogen activator inhibitor-1 (PAI-1)...
  77. ncbi Indication of a role of plasminogen activator inhibitor type I in protecting murine fibrosarcoma cells against apoptosis
    Maria Unni Rømer
    Institute of Veterinary Pathobiology, The Royal Veterinary and Agricultural University, Frederiksberg C, Denmark
    Thromb Haemost 94:859-66. 2005
    In a number of cancer types high tumor tissue levels of plasminogen activator inhibitor type 1 (PAI-1) protein are strongly associated with shorter cancer patient survival...
  78. ncbi Genetic polymorphisms at FCER1B and PAI-1 and asthma susceptibility
    N Hizawa
    First Department of Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan
    Clin Exp Allergy 36:872-6. 2006
    ..A genetic interaction is biologically plausible between FcepsilonRI-beta and the plasminogen activator inhibitor 1 (PAI-1), which is highly expressed in mast cells in asthmatics and plays an essential role in airway ..
  79. ncbi Relationship between polymorphisms in thrombophilic genes and preeclampsia in a Brazilian population
    C A Dalmáz
    Departamento de Genetica, Instituto de Biociencias, Universidade Federal do Rio Grande do Sul, Caixa Postal 15053, 91 501 970 Porto Alegre, RS, Brazil
    Blood Cells Mol Dis 37:107-10. 2006
    ..11, 95% CI 0.89-73.92; factor V Leiden (FV Leiden) OR 3.94, 95% CI 0.35-44.23; plasminogen activator inhibitor (PAI-1) 4G/4G genotype, OR 1.63, 95% CI 0.87-3.05] not even with severe preeclampsia subgroup analysis...
  80. doi The impact of the PAI-1 4G/5G polymorphism on the outcome of patients with ALI/ARDS
    Iraklis Tsangaris
    2nd Department of Critical Care Medicine, Attikon Hospital, Medical School, University of Athens, Athens, Greece
    Thromb Res 123:832-6. 2009
    Increased levels of plasminogen activator inhibitor-1 (PAI-1) have been associated with worse outcome in ALI/ARDS...
  81. doi Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1
    Mirjam E Meltzer
    Department of Clinical Chemistry and Hematology, University Medical Center Utrecht, Utrecht, The Netherlands
    Blood 116:113-21. 2010
    ..Plasminogen activator inhibitor-1 (PAI-1) levels were the main determinants of CLT, followed by plasminogen, thrombin-activatable fibrinolysis inhibitor (..
  82. pmc Silencing of DLC1 upregulates PAI-1 expression and reduces migration in normal prostate cells
    Yi Ping Shih
    Center for Tissue Regeneration and Repair, University of California Davis, Sacramento, California 95817, USA
    Mol Cancer Res 10:34-9. 2012
    ..This migration defect is mainly due to upregulation of plasminogen activator inhibitor 1 (PAI-1). Silencing of PAI-1 rescues the shDLC1-reduced migration phenotype...
  83. pmc Relationship of metabolic syndrome and its components with -844 G/A and HindIII C/G PAI-1 gene polymorphisms in Mexican children
    Ulises De la Cruz-Mosso
    Unidad Académica de Ciencias Químico Biológicas, Universidad Autonoma de Guerrero, Avenida Lázaro Cárdenas s n, Ciudad Universitaria, Chilpancingo, Guerrero CP 39090, Mexico
    BMC Pediatr 12:41. 2012
    Several association studies have shown that -844 G/A and HindIII C/G PAI-1 polymorphisms are related with increase of PAI-1 levels, obesity, insulin resistance, glucose intolerance, hypertension and dyslipidemia, which are components of ..
  84. doi Promoter polymorphisms of SERPINE1 are associated with the antidepressant response to depression in Alzheimer's disease
    Yu Fang
    Key Disciplines Laboratory Clinical Medicine Henan, Department of Emergency, The First Affiliated Hospital, College of Medicine, Zhengzhou University, Zhengzhou, PR China
    Neurosci Lett 516:217-20. 2012
    ..of the tissue plasminogen activator/brain-derived neurotrophic factor axis, plasminogen activator inhibitor-1 (PAI-1) is involved in the pathogenesis of both AD and depression...
  85. doi Plasminogen activator inhibitor-1 gene polymorphism in Iranian Azeri Turkish patients with FMF disease and its association with amyloidosis
    M Bonyadi
    Center of Excellence for Biodiversity, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran
    Eur J Pediatr 172:91-8. 2013
    ..b>Plasminogen activator inhibitor 1 (PAI-1) is a key element in the inhibition of fibrinolysis by inactivating tissue-type and urokinase-..
  86. doi Plasminogen activator inhibitor 1 4G/5G and -844G/A variants in idiopathic recurrent pregnancy loss
    Kalthoum Magdoud
    Research Unit of Hematological and Autoimmune Diseases, Faculty of Pharmacy, University of Monastir, Monastir, Tunisia
    Am J Reprod Immunol 70:246-52. 2013
    Plasminogen activator inhibitor type 1 (PAI-1) regulates fibrinolysis, and the common promoter region variants -675G/A (4G/5G) and -844G/A are associated with increased thrombotic risk...
  87. doi Prognostic value of pre-surgical plasma PAI-1 (plasminogen activator inhibitor-1) levels in breast cancer
    Raffaele Palmirotta
    Department of Laboratory Medicine and Advanced Biotechnologies, IRCCS San Raffaele Pisana, via della Pisana 235, Rome, Italy
    Thromb Res 124:403-8. 2009
    Plasminogen activator inhibitor (PAI-1) may have an independent prognostic value in breast cancer (BC). PAI-1 4G/5G polymorphism may have significance for antigen expression...
  88. doi Plasminogen activator inhibitor-1 (PAI-1) activity and retinal vascular calibre in type 2 diabetes
    L Brazionis
    Department of Medicine, University of Melbourne, St Vincent s Hospital, Australia
    Diabetes Res Clin Pract 87:192-9. 2010
    To describe relationships of retinal vascular calibre with plasminogen activator inhibitor-1 (PAI-1) and other cardiovascular risk factors in people with type 2 diabetes.
  89. ncbi Plasma PAI-1 levels in obese children--effect of weight loss and influence of PAI-1 promoter 4G/5G genotype
    A Estelles
    Research Center, La Fe University Hospital, Valencia, Spain
    Thromb Haemost 86:647-52. 2001
    An association between an increase in plasminogen activator inhibitor type 1 (PAI-1) and obesity, and also between elevated levels of PAI-1 and the presence of PAI-1 promoter 4G allele has been described in adults and can contribute to ..
  90. ncbi [Association of plasminogen activator inhibitor-1 gene 4G/5G polymorphism and coronary heart disease in Chinese patients]
    Lixue Guan
    Weifang People s Hospital, Weifang, Shandong, 261041 P R China
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi 19:393-6. 2002
    To assess whether the plasminogen activator inhibitor-1 (PAI-1) gene 4G/5G polymorphism is associated with coronary heart disease (CHD) in Chinese patients.
  91. doi Distribution of --844 G/A and Hind III C/G PAI-1 polymorphisms and plasma PAI-1 levels in Mexican subjects: comparison of frequencies between populations
    Norma Torres-Carrillo
    Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, Departamento de Biología Molecular y Genómica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
    Clin Appl Thromb Hemost 14:220-6. 2008
    Several polymorphisms have been described in the PAI-1 gene including the -844 G/A and Hind III C/G polymorphisms. These polymorphisms have been associated with different diseases such as preeclampsia and cardiovascular diseases...
  92. doi PAI-1 gene 4G/5G polymorphism, cytokine levels and their relations with metabolic parameters in obese children
    Sibel Tulgar Kinik
    Baskent University Faculty of Medicine, 6 Cadde 70 1, 06490 Bahcelievler, Ankara, Turkey
    Thromb Haemost 99:352-6. 2008
    Obesity is associated with the changes of plasminogen activator inhibitor-1 (PAI-1), tumor necrosis factor-alpha (TNFalpha) and transforming growth factor beta (TGFbeta) levels...
  93. doi Plasminogen activator inhibitor-1 gene 4G/5G polymorphism in Turkish children with asthma and allergic rhinitis
    Ozlem Yilmaz Ozbek
    Department of Pediatric Allergy, Baskent University Faculty of Medicine, Ankara, Turkey
    Allergy Asthma Proc 30:41-6. 2009
    Plasminogen activator inhibitor (PAI-1) has an essential role in tissue remodeling after inflammation...
  94. doi Plasminogen activator inhibitor-1 C/G polymorphism in relation to plasma levels in rheumatoid arthritis
    Norma Torres-Carrillo
    Departamento de Biología Molecular y Genómica, Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
    Clin Exp Med 9:223-8. 2009
    Plasminogen activator inhibitor type 1 (PAI-1) is an inhibitor of plasmin production. Plasmin can directly or indirectly to degrade cartilage and bone matrix...
  95. doi Reduced carriership of 4G allele of plasminogen activator inhibitor-1 4G/5G polymorphism in very young survivors of myocardial infarction
    Loukianos S Rallidis
    Second Department of Cardiology, Attikon Hospital, School of Medicine, University of Athens, Athens, Greece
    J Thromb Thrombolysis 29:497-502. 2010
    ..limited and controversial data regarding the impact of 4G/5G polymorphism of the plasminogen activator inhibitor-1 (PAI-1) gene in the pathogenesis of premature myocardial infarction (MI)...
  96. doi Contribution of genetic and metabolic syndrome to omental adipose tissue PAI-1 gene mRNA and plasma levels in obesity
    Luigi Bouchard
    Department of Medicine, ECOGENE 21 and Lipid Clinic, Chicoutimi Hospital, Universite de Montreal, Saguenay, QC, Canada
    Obes Surg 20:492-9. 2010
    Plasminogen activator inhibitor type-1 (PAI-1) has already been associated with atherosclerosis; myocardial infarction; and cardiovascular disease risk factors such as obesity, insulin resistance, and dyslipidemia...
  97. doi Plasminogen activator inhibitor-1 polymorphisms (-844 G>A and HindIII C>G) in systemic lupus erythematosus: association with clinical variables
    Jorge Ramón Padilla-Gutiérrez
    Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, Departamento de Biología Molecular y Genómica, Centro Universitario de Ciencias de Salud, Universidad de Guadalajara, Insurgentes 244 1, Colonia Lomas de Atemajac, 45178 Zapopan, Jalisco, Mexico
    Clin Exp Med 11:11-7. 2011
    ..demonstrated mechanisms responsible for modulation of the immune response by the plasminogen activator inhibitor-1 (PAI-1). Furthermore, the endogenous PAI-1 has shown to promote a Th2 immune response...
  98. doi Platelet polymorphisms: frequency distribution and association with coronary artery disease in an Indian population
    Tester F Ashavaid
    Research Laboratories, P D Hinduja National Hospital and Medical Research Centre, V S Marg, Mahim, Mumbai, India
    Platelets 22:85-91. 2011
    ..chain (BclI), α-chain (Aα312), tissue plasminogen activator (tPA) [I/D] and plasminogen activator inhibitor-I (PAI-1) [4G/5G] in 473 healthy controls and 446 patients with stable and unstable angina...
  99. doi SERPINE1 -675 4G/5G polymorphism is associated with asthma severity and inhaled corticosteroid response
    A Dijkstra
    Dept of Pulmonology, Center Groningen and University of Groningen, Groningen, The Netherlands
    Eur Respir J 38:1036-43. 2011
    ..These findings suggest that SERPINE1 is not an asthma susceptibility gene, but rather affects the severity, progression and long-term ICS response in asthma...
  100. doi Significant down-regulation of the plasminogen activator inhibitor 1 mRNA in pancreatic cancer
    Ute Warnecke-Eberz
    Department of Visceral and Vascular Surgery, University of Cologne, Cologne, Germany
    Pancreas 36:173-7. 2008
    ..mRNA expression of the urokinase-type plasminogen activator (uPA), its receptor (uPAR), and the plasminogen activator inhibitor 1 (PAI-1) in a panel of adenocarcinomas of the pancreas (PC) and cancers of the papilla of Vater (CPV)...
  101. ncbi Plasminogen activator inhibitor-1 gene polymorphism and colorectal cancer risk and prognosis
    Alexandre Loktionov
    MRC Dunn Human Nutrition Unit, Wellcome Trust MRC Building, Hills Road, Cambridge CB2 2XY, UK
    Cancer Lett 189:189-96. 2003
    Plasminogen activator inhibitor-1 (PAI-1) is a factor in urokinase-type plasminogen activator proteolytic system, which is important for tumour invasion and metastasis. Elevated PAI-1 levels in tumours are associated with poor prognosis...

Research Grants64

  1. Novel Targets in Thrombosis and Atherosclerosis
    Daniel A Lawrence; Fiscal Year: 2012
    ..has been identified as playing a role in both inflammation and thrombosis is plasminogen activator inhibitor-1 (PAI-1), and very recent data suggests that PAI-1 may also play a role in regulating lipid metabolism...
  2. Workshop on the Molecular and Cellular Biology of Plasminogen Activation
    Victoria Ploplis; Fiscal Year: 2013
    ..The major inhibitor of Pg activation, Plasminogen Activator Inhibitor-1 (PAI-1), regulates this process at the level of the primary physiological activators, urokinase-type plasminogen ..
  3. Biomarkers of Vascular Disease Progression in Type 1 Diabetes Mellitus
    Maria F Lopes-Virella; Fiscal Year: 2011
    ....
  4. William P Fay; Fiscal Year: 2016
    ..Plasminogen activator inhibitor-1 (PAI-1) is a serine protease inhibitor and a major regulator of fibrinolysis and cell migration...
  5. RICHARD LOUIS KLEIN; Fiscal Year: 2015
    ..contains higher concentrations of S1P than HDL2, both stimulate the release of plasminogen activator inhibitor-1 (PAI-1) from adipocytes and, importantly, that circulating S1P concentrations are significantly increased in patients ..
  6. Urokinase, Neutrophil Activation and Acute Lung Injury.
    Gang Liu; Fiscal Year: 2013
    ..pathways, associated with increases in circulating and pulmonary concentrations of urokinase (uPA), plasminogen activator inhibitor 1 (PAI-1), and vitronectin, are present in almost all patients with acute lung injury (ALI)...
  7. DOUGLAS EUGENE VAUGHAN; Fiscal Year: 2016
    ..for this association, we have focused on the interaction between the RAAS and plasminogen activator inhibitor-1 (PAI-1)...
  8. REGULATION OF VASCULAR FIBRINOLYSIS
    David Loskutoff; Fiscal Year: 2003
    b>Plasminogen activator inhibitor 1 (PAI-1) is the primary inhibitor of plasminogen activation and vascular fibrinolysis in vivo, and elevations in PAI-1 appear to compromise normal fibrin clearance mechanisms and promote pathological ..
  9. MOLECULAR INTERACTIONS OF FIBRINOLYSIS
    John Anagli; Fiscal Year: 2005
    ..on a molecular level, the mechanisms of inhibitory control of fibrinolysis by plasminogen activator inhibitor-1 (PAI-1)...
  10. Zhongwu Liu; Fiscal Year: 2014
    ..activity of tissue plasminogen activator (tPA) via modifying the balance of tPA/plasminogen activator inhibitor-1(PAI-1) level...
  11. Regulation of Pal-1 in Atherosclerosis and Thrombosis
    Yolanda M Fortenberry; Fiscal Year: 2013
    ..and hypertension. Elevated plasma levels of the serine protease inhibitor, plasminogen activatoMnhibitor-1, (PAI- 1) are correlated with these'risk factors and:several other thrombotic disorders..PAI-1.is the-...
  12. Maria Mori Brooks; Fiscal Year: 2014
    ..During the five- year follow-up, plasminogen activator inhibitor-1 (PAI-1), C-reactive protein (CRP), fibrinogen, and D-dimer were lower in the insulin sensitization group compared with ..
  13. ANGARA KONETI RAO; Fiscal Year: 2016
    ..VIIa, and VIII~ plasma TAT~ D-dimer~ tissue factor pathway inhibitor (TFPI)~ and plasminogen activator inhibitor-1 (PAI-1)] will be measured before and at 48 hours after the start of treatment...
  14. KLF2 as a regulator of endothelial cell biology
    MUKESH KUMAR JAIN; Fiscal Year: 2012
    ..abstract_text> ..
  15. Preclinical Development of a Novel Plaque-Regressing Therapy For Atherosclerosis
    Michael W Fanger; Fiscal Year: 2012
    ..Success would ultimately provide a profound medical advancement in treatment of atherosclerosis, a significant benefit to human health, and a dramatic reduction in the economic impact of the number one killer in America. ..
  16. Anne S Henkel; Fiscal Year: 2016
    ..patients with NASH have increased circulating levels and hepatic expression of plasminogen activator inhibitor-1 (PAI-1), however it is unknown whether this association is causative or simply correlative...
  17. Autonomic, Endothelial, and Inflammatory Correlates of Sleep Duration
    MERCEDES RENEE CARNETHON; Fiscal Year: 2012
    ..Findings from this study will suggest mechanisms to explain the prior observed associations between sleep duration and CVD risk factors. ..
  18. Karen Block; Fiscal Year: 2015
    ..protein degradation by inducing inhibitors of matrix-degrading enzymes such as plasminogen activator inhibitor-1 (PAI-I)...
  19. Punam Malik; Fiscal Year: 2016
    ..expression of the potent pulmonary vasoconstrictor ET-1, and a procoagulant, plasminogen activator inhibitor-1 (PAI-1), from human pulmonary microvascular endothelial cells (HPMVEC)...
  20. Dichotomous Roles of Thrombin in Acetaminophen Hepatotoxicity
    ROBERT ANDREW ROTH; Fiscal Year: 2013
    ..The deposition of fibrin is enhanced by the antifibrinolytic activity of plasminogen activator inhibitor-1 (PAI-1), a plasma protein the expression of which is induced by the transcription factor, hypoxia inducible factor-..
  21. Inflammation and Injury in Obesity Hypertension in African American Adolescents
    Bonita Falkner; Fiscal Year: 2010
    ..abstract_text> ..
  22. Yves A DeClerck; Fiscal Year: 2016
    DESCRIPTION (provided by applicant): Plasminogen activator inhibitor-1 (PAI-1) is a member of the family of endogenous serine protease inhibitors (serpins) that controls the activation of plasminogen into plasmin by tissue and urokinase ..
  23. Elena Barengolts; Fiscal Year: 2014
    ....
  24. PAI-1 and Vitronectin in Failure of Coronary Revascularization
    William P Fay; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Plasminogen activator inhibitor-1 (PAI-1) is the primary inhibitor of tissue- and urinary-type plasminogen activators...
  25. Regulation of Transcriptional Activity of Hypoxia Inducible Factor 2
    Cheng Jun Hu; Fiscal Year: 2012
    ..First, HIF2( and USF2 share a large number of common target genes. An example of such gene is the plasminogen activator inhibitor 1 (PAI1)...
  26. Ah Receptor Anatomy: Implications for Dioxin Toxicity
    CORNELIS JOHAN ELFERINK; Fiscal Year: 2011
    ..and relative contribution of cyclin-dependent kinase 2 (CDK2) inhibi- ion and plasminogen activator inhibitor-1 (PAI-1) expression on liver regeneration...
  27. Gary W Hoyle; Fiscal Year: 2016
    ..This type of research is important because of concerns that U.S. civilians could be adversely affected by the accidental or intentional release of highly toxic chemicals such as chlorine. ..
  28. Pathogenesis of Lymphangioleiomyomatosis
    Lucia Schuger; Fiscal Year: 2010
    ..corresponding inhibitors, tissue inhibitor of metalloproteinases-3 (TIMP-3) and plasminogen activator inhibitor-1 (PAI-1) are downregulated, resulting in an enzymatic imbalance that favors ECM degradation...
  29. Yi Ping Shih; Fiscal Year: 2016
    ..I have also discovered that loss of DLC1 enhances angiogenesis by upregulating VEGF and plasminogen activator inhibitor 1 (PAI-1) expression...
  30. Ah receptor transcriptional regulation through a novel DNA binding site
    SHELLY RENEE WILSON; Fiscal Year: 2012
    ..Preliminary evidence examining TCDD induction of plasminogen activator inhibitor-1 (PAI-1), a key protein in liver regeneration, exposed a novel AhR-dependent regulatory mechanism involving DNA binding ..
  31. BMP Regulation of TGF-b2 in the Trabecular Meshwork
    Robert J Wordinger; Fiscal Year: 2012
    ..indicates that (a) BMP-4 inhibits TGF-22 stimulation of fibronectin (FN) and plasminogen activator inhibitor-1 (PAI-1) secretion by cultured TM cells and (b) gremlin, a BMP antagonist is upregulated in multiple glaucomatous TM cell ..
  32. Exercise Effects on Serum Biomarkers of Angiogenesis
    CATHERINE ROSE DUGGAN; Fiscal Year: 2012
    ..growth factor (VEGF), osteopontin, pigment epithelium-derived factor (PEDF) and plasminogen activator inhibitor-1(PAI-1)...
  33. Role of plasminogen activator inhibitor-1 in mediating age-related fibrosis
    David Lu; Fiscal Year: 2013
    ..While numerous studies have correlated increases in plasminogen activator inhibitor-1 (PAI-1) with aging, none have directly examined possible mechanisms of PAI-1-mediated inhibition of collagen turnover...
  34. The role of Plasminogen activator Inhibitor-1 in Helicobacter pylori infection.
    Sarah E Keates; Fiscal Year: 2010
    ..with the bacterial pathogen Helicobacter pylori causes an upregulation of Plasminogen activator inhibitor-1 (PAI-1), which contributes to gastric cancer progression. Aim 1 examines how H...
  35. Regulation of Host Response in S. pneumoniae Infections
    Jian dong Li; Fiscal Year: 2010
    ..We also found that CYLD inhibits MKK3-p38-dependent type 1 plasminogen activator inhibitor (PAI1) expression in lung, thereby potentiating alveolar hemorrhage and early lethality...
  36. CONTROL OF DRUG AND ETHANOL METABOLISM
    Gavin E Arteel; Fiscal Year: 2010
    ..Specifically, we showed that hepatic expression of plasminogen activator inhibitor-1 (PAI-1) is upregulated by ethanol and the level of expression correlates with protection against liver damage in enteral ..
  37. "Validation of Novel CKD Biomarkers in CRIC"
    Kathleen D Liu; Fiscal Year: 2013
    ....
  38. Agnes B Fogo; Fiscal Year: 2016
    ..we have shown that high doses of angiotensin inhibition, linked to decreased plasminogen activator inhibitor-1 (PAI-1), could regress existing glomerulosclerosis over the short term...
  39. Mechanism of PAI-1 Polarization to Myoendothelial Junctions
    Brant E Isakson; Fiscal Year: 2013
    ..During the course of metabolic syndrome, there is a significant increase in plasminogen activator inhibitor-1 (PAI-1);however the pathological role that PAI-1 plays during the course of the disease is not clear...
  40. DANIELLE S BENOIT; Fiscal Year: 2016
    ..fibrosis in a variety of pathologies is associated with TGF-21 induction of plasminogen activator inhibitor-1 (PAI-1) that prevents activation of MMPs, TGF-23 has anti-scarring effects in cutaneous wound healing...
  41. PAI-1 Targeted Intrapleural Fibronolytic Therapy
    Andrey Komissarov; Fiscal Year: 2012
    ..These are important clinical problems that mandate the search for better IPFT. Plasminogen activator inhibitor-1 (PAI-1) is strongly implicated in the pathogenesis of pleural loculation and inhibits tissue and urokinase plasminogen ..
  42. Mechanisms of Hemostatic Protease Inhibition by Serpins
    Ingrid M Verhamme; Fiscal Year: 2010
    ..of thrombin (T) inhibition by the serpins, heparin cofactor II (HCII) and plasminogen activator inhibitor-1 (PAI-1), implicated in arterial thrombosis...
  43. ACE Inhibition and Novel Cardiovascular Risk Factors
    Marco Pahor; Fiscal Year: 2004
    ..But, clinical trial evidence on these effects is limited. In addition, polymorphisms of the ACE, angiotensinogen, PAI-1 and IL-6 genes may modify the therapeutic response to ACE inhibitors...
  44. REGULATION OF ANGIOGENESIS BY PAI1
    Daniel Lawrence; Fiscal Year: 2001
    ..of the anti-angiogenic effect observed in our preliminary studies with plasminogen activator inhibitor-1 (PAI-1)...
  45. MECHANISMS UNDERLYING CARDIOVASCULAR RISKS IN DIABETES
    Gordon Williams; Fiscal Year: 2000
    ..and hyperglycemia in combination with differences in the specific alleles of the genes of the renin-angiotensin and PAI-1 systems that predispose the individual to vascular complications...
  46. Enhancement of Thrombolysis through Inhibition of PAI-1 and Antiplasmin
    CHARLENE BLAKE; Fiscal Year: 2007
    ..central hypothesis that reversible inhibition of the antifibrinolytic proteins plasminogen activator inhibitor-1 (PAI-1) and antiplasmin through aptamer-antidote pairs can produce safe and effective thrombolysis for treatment of ..
  47. GENETIC ARCHITECTURE OF PLASMA T-PA AND PAI-1
    Jason Moore; Fiscal Year: 2004
    ..In particular, elevated plasma levels of plasminogen activator inhibitor-1 (PAI-1), tissue-type plasminogen activator (T-PA), NAD T-PA/PA-1 complexes have been found to correlate with increased ..
  48. GENETIC VARIANTS AND THROMBOSIS
    Patricia Hebert; Fiscal Year: 2004
    ..In particular, elevated plasma levels of plasminogen activator inhibitor-1 (PAI-1), tissue-type plasminogen activator (t-PA), and t-PA/PAI-1 complexes have been found to correlate with increased ..
  49. PLASMINOGEN ACTIVATOR INHIBITOR-1 IN ATHEROSCLEROSIS
    DANIEL EITZMAN; Fiscal Year: 2001
    ..RESEARCH PROPOSAL: The goal of this grant is to define the role of type I plasminogen activator inhibitor (PAI-1) in the development of intimal lesion formation during atherogenesis and following vascular injury...
  50. MECHANISMS OF CARDIOVASCULAR DISEASE IN OBESITY
    David Loskutoff; Fiscal Year: 2002
    ..Although plasminogen activator inhibitor 1 (PAI-1) is consistently and significantly elevated in the plasma of obese humans and is a known risk ..
  51. PATHOGENESIS OF RADIATION-INDUCED KIDNEY INJURY
    Michael Robbins; Fiscal Year: 2004
    ..with radiation, Ang II and other ROS generators in vitro leads to modulation of plasminogen activator inhibitor-1 (PAI-1), tissue inhibitor of metalloproteinases-2 (TIMP-2) matrix metalloproteinase-2 (MMP-2), TGF-B and angiotensinogen ..
  52. VASCULAR DISEASE IN HBP--ANGII, PAI1, INSULIN AND GENES
    Gordon Williams; Fiscal Year: 2001
    ..to address three of these: 1) the renin-angiotensin system (RAS), 2) the plasminogen- activator-inhibitor-1 (PAI-1) system, and 3) the metabolic abnormalities associated with insulin resistance...
  53. AGE RELATED CONFORMATIONAL MODIFICATIONS OF PROTEIN
    Ari Gafni; Fiscal Year: 2003
    ..enzyme phosphoglycerate kinase (PGK) and the fibrinolysis-associated protein plasminogen activator inhibitor-1 (PAI-1)...
  54. Regulation of angiotensin-induced PAI-1 expression
    EDWARD FEENER; Fiscal Year: 2006
    ..and from other groups, have demonstrated that AngII is a potent stimulator of plasminogen activator inhibitor-1(PAI-1) expression in cultured vascular cells and RAS inhibition reduces neointimal PAI-1 expression in vascular tissues ..
  55. Cardiac Risk:Insulin Resistance, Hypertension, & PAI-1
    Abraham Thomas; Fiscal Year: 2006
    ..Plasminogen activator inhibitor-1 (PAI-1) is an important peptide in the fibrinolytic-thrombotic pathway and elevated levels of PAI-1 have been shown to ..
  56. PPARGAMMA AND AII IN GLOMERULOSCLEROSIS
    Willa Hsueh; Fiscal Year: 2002
    ..Plasminogen activator inhibitor-1 (PAI-1) is produced by mesangial cells in response to growth factor stimulation, is increased in glomeruli of diabetic ..
  57. TLR2 in Sepsis-Induced Coagulopathy, Endothelial Leak, and Pulmonary Dysfunction
    Judith Hellman; Fiscal Year: 2010
    ..of tissue factor (TF), tissue factor pathway inhibitor (TFPI), and plasminogen activator inhibitor type 1 (PAI-1) will be quantified...
  58. Deranged Coagulation and Fibrinolytic Cascades in Idiopathic Pulmonary Fibrosis
    MITCHELL ALAN OLMAN; Fiscal Year: 2013
    ..there is activation of coagulation (increased tissue factor antigen), and inhibition of fibrinolysis (increased PAI-1 antigen) in plasma from patients with IPF...
  59. Toni M Antalis; Fiscal Year: 2016
    ..Objectives: Using clinically relevant experimental models of DVT, we discovered that genetic deletion of PAI- 2 in mice accelerates venous thrombus resolution...
  60. Zheng Gang Zhang; Fiscal Year: 2016
    ..and astrocytes, which leads to reduction of thrombosis by downregulation of plasminogen activator inhibitor1 (PAI-1)...
  61. Coagulation Abnormalities and Post-Traumatic Ventilator-Associated Pneumonia
    Jean Francois Pittet; Fiscal Year: 2013
    ..with (a) low plasma levels of aPC and (b) an inhibition of the fibrinolysis caused by elevated plasma levels of PAI-1...
  62. ENDOTHELIAL CELL PLASMINOGEN ACTIVATOR INHIBITOR TYPE 2
    Raymond Schleef; Fiscal Year: 1990
    ..that cultured ECs also produce two immunological distinct plasminogen activator inhibitors, including both type 1 (PAI-1) and type 2 (PAL-2), introduces a previously unsuspected level of complexity to our understanding of this system, ..
  63. CONTROL OF FIBRIN TURNOVER IN PLEURAL DISEASE
    Steven Idell; Fiscal Year: 2004
    ..Derangements of the regulation of plasminogen activator inhibitor -1 (PAI-1) and the urokinase receptor (uPAR) by pleural mesothelial cells appear to be critical determinants of locally ..
  64. HUMAN PLASMINOGEN ACTIVATOR-INHIBITOR PAI-1 GENE
    David Ginsburg; Fiscal Year: 1991
    ..plasminogen activator (tPA) and its specific, rapidly acting inhibitor, plasminogen activator inhibitor (PAI-1)...